Clearmind Medicine Inc. Common Shares
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It d… Read more
Clearmind Medicine Inc. Common Shares (CMND) - Net Assets
Latest net assets as of October 2025: $1.67 Million USD
Based on the latest financial reports, Clearmind Medicine Inc. Common Shares (CMND) has net assets worth $1.67 Million USD as of October 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.53 Million) and total liabilities ($6.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.67 Million |
| % of Total Assets | 19.61% |
| Annual Growth Rate | N/A |
| 5-Year Change | -56.86% |
| 10-Year Change | N/A |
| Growth Volatility | 339.4 |
Clearmind Medicine Inc. Common Shares - Net Assets Trend (2014–2025)
This chart illustrates how Clearmind Medicine Inc. Common Shares's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Clearmind Medicine Inc. Common Shares (2014–2025)
The table below shows the annual net assets of Clearmind Medicine Inc. Common Shares from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-10-31 | $1.67 Million | -61.36% |
| 2024-10-31 | $4.33 Million | +339.84% |
| 2023-10-31 | $983.47K | +165.51% |
| 2022-10-31 | $-1.50 Million | -138.74% |
| 2021-10-31 | $3.87 Million | +933.86% |
| 2020-10-31 | $374.78K | +268.78% |
| 2019-10-31 | $101.63K | -44.23% |
| 2018-10-31 | $182.24K | +269.18% |
| 2017-10-31 | $49.36K | +208.00% |
| 2016-10-31 | $-45.71K | -112.66% |
| 2015-10-31 | $-21.49K | -15.33% |
| 2014-10-31 | $-18.64K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Clearmind Medicine Inc. Common Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3905544100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (October 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $37.00 Million | 2213.88% |
| Other Comprehensive Income | $-29.78K | -1.78% |
| Other Components | $3.77 Million | 225.63% |
| Total Equity | $1.67 Million | 100.00% |
Clearmind Medicine Inc. Common Shares Competitors by Market Cap
The table below lists competitors of Clearmind Medicine Inc. Common Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Micro2Nano Inc.
KO:424980
|
$88.41K |
|
BTIP39
SA:BTIP39
|
$88.45K |
|
Galapagos Recebiveis Do Agronegocio Fiagro Imobiliario
SA:GCRA11
|
$88.51K |
|
Urban Logistics Reit PLC
LSE:SHED
|
$88.51K |
|
Lake Winn Resources Corp
PINK:EQTXF
|
$88.26K |
|
BSGO39
SA:BSGO39
|
$88.26K |
|
GENERALE DE SANTE
BE:GD6
|
$88.23K |
|
Cemex SAB de CV
STU:CEXA
|
$88.23K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Clearmind Medicine Inc. Common Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,325,712 to 1,671,482, a change of -2,654,230 (-61.4%).
- Net loss of 5,405,754 reduced equity.
- Other comprehensive income decreased equity by 202.
- Other factors increased equity by 2,751,726.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.41 Million | -323.41% |
| Other Comprehensive Income | $-202.00 | -0.01% |
| Other Changes | $2.75 Million | +164.63% |
| Total Change | $- | -61.36% |
Book Value vs Market Value Analysis
This analysis compares Clearmind Medicine Inc. Common Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.05x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-10-31 | $161.55 | $0.68 | x |
| 2018-10-31 | $676.24 | $0.68 | x |
| 2019-10-31 | $329.60 | $0.68 | x |
| 2020-10-31 | $826.87 | $0.68 | x |
| 2021-10-31 | $5013.86 | $0.68 | x |
| 2022-10-31 | $-1386.13 | $0.68 | x |
| 2023-10-31 | $194.29 | $0.68 | x |
| 2024-10-31 | $55.81 | $0.68 | x |
| 2025-10-31 | $13.15 | $0.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Clearmind Medicine Inc. Common Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -323.41%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 5.10x
- Recent ROE (-323.41%) is below the historical average (-173.15%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-31.37K |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-44.71K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-19.64K |
| 2017 | -13.23% | 0.00% | 0.00x | 2.04x | $-11.47K |
| 2018 | -106.75% | 0.00% | 0.00x | 1.03x | $-212.76K |
| 2019 | -103.60% | 0.00% | 0.00x | 1.33x | $-115.45K |
| 2020 | -62.23% | 0.00% | 0.00x | 1.03x | $-270.70K |
| 2021 | -94.36% | 0.00% | 0.00x | 1.07x | $-4.04 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.78 Million |
| 2023 | -1205.11% | 0.00% | 0.00x | 6.05x | $-11.95 Million |
| 2024 | -169.09% | 0.00% | 0.00x | 2.33x | $-7.75 Million |
| 2025 | -323.41% | 0.00% | 0.00x | 5.10x | $-5.57 Million |
Industry Comparison
This section compares Clearmind Medicine Inc. Common Shares's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Clearmind Medicine Inc. Common Shares (CMND) | $1.67 Million | 0.00% | 4.10x | $88.30K |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |